WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering for $3.39 Million

✦ Meridian Analysis

ABVC BioPharma has closed a private placement of original‑issue‑discount senior convertible promissory notes, generating roughly $3.39 million in gross proceeds. The notes carry a 17.5 % original issue discount, an aggregate principal of $4,106,060, and mature on 30 June 2027. Institutional and accredited investors purchased the securities under a securities purchase agreement, with WallachBeth Capital acting as the placement agent. The instruments are convertible after eight months at a price equal to 85 % of the average three‑day VWAP of ABVC’s common stock, subject to a floor price and customary adjustments. The company will apply the net proceeds to general working capital, fund its subsidiaries, and settle a $625,000 claim with Lind Global Fund IILP, thereby supporting its broader licensing and development strategy across CNS, oncology, ophthalmic devices and contract manufacturing platforms. The next steps include filing ABVC’s Form 8‑K and monitoring the eight‑month conversion window.

The Meridian Weekly